BrAD-R13

N/A

Report date: 2023/03/23 13:51:06
NME

Base Information

Drug NameBrAD-R13
Drug Alias NameBrAD-R13BrADR13
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurotrophic tyrosine kinase receptor type 2 stimulants
TargetsNeurotrophic tyrosine kinase receptor type 2
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Braegen Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen Braegen Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A